Clinical Reasoning: Assessing New Neurologic Deficits in Patients With Hematologic Malignancy on Bruton Tyrosine Kinase Inhibitor Therapy.
Saved in:
| Title: | Clinical Reasoning: Assessing New Neurologic Deficits in Patients With Hematologic Malignancy on Bruton Tyrosine Kinase Inhibitor Therapy. |
|---|---|
| Authors: | Nelson TA; From the Division of Neuro-Oncology (T.A.N., N.K.M., I.C.A.-R., N.W., J.D.), Department of Neurology; Department of Pathology (M.M.-L.A.); Division of Hematology and Oncology (J.A., A.R.B., Y.J., Y.-B.A.C.), Department of Medicine; Division of Infectious Diseases (A.R.L.), Department of Medicine; and Department of Neurosurgery (B.V.N.), Massachusetts General Hospital, Boston., Murthy NK; From the Division of Neuro-Oncology (T.A.N., N.K.M., I.C.A.-R., N.W., J.D.), Department of Neurology; Department of Pathology (M.M.-L.A.); Division of Hematology and Oncology (J.A., A.R.B., Y.J., Y.-B.A.C.), Department of Medicine; Division of Infectious Diseases (A.R.L.), Department of Medicine; and Department of Neurosurgery (B.V.N.), Massachusetts General Hospital, Boston., Martinez-Lage M; From the Division of Neuro-Oncology (T.A.N., N.K.M., I.C.A.-R., N.W., J.D.), Department of Neurology; Department of Pathology (M.M.-L.A.); Division of Hematology and Oncology (J.A., A.R.B., Y.J., Y.-B.A.C.), Department of Medicine; Division of Infectious Diseases (A.R.L.), Department of Medicine; and Department of Neurosurgery (B.V.N.), Massachusetts General Hospital, Boston., Abramson J; From the Division of Neuro-Oncology (T.A.N., N.K.M., I.C.A.-R., N.W., J.D.), Department of Neurology; Department of Pathology (M.M.-L.A.); Division of Hematology and Oncology (J.A., A.R.B., Y.J., Y.-B.A.C.), Department of Medicine; Division of Infectious Diseases (A.R.L.), Department of Medicine; and Department of Neurosurgery (B.V.N.), Massachusetts General Hospital, Boston., Branagan AR; From the Division of Neuro-Oncology (T.A.N., N.K.M., I.C.A.-R., N.W., J.D.), Department of Neurology; Department of Pathology (M.M.-L.A.); Division of Hematology and Oncology (J.A., A.R.B., Y.J., Y.-B.A.C.), Department of Medicine; Division of Infectious Diseases (A.R.L.), Department of Medicine; and Department of Neurosurgery (B.V.N.), Massachusetts General Hospital, Boston., Ji Y; From the Division of Neuro-Oncology (T.A.N., N.K.M., I.C.A.-R., N.W., J.D.), Department of Neurology; Department of Pathology (M.M.-L.A.); Division of Hematology and Oncology (J.A., A.R.B., Y.J., Y.-B.A.C.), Department of Medicine; Division of Infectious Diseases (A.R.L.), Department of Medicine; and Department of Neurosurgery (B.V.N.), Massachusetts General Hospital, Boston., Chen YA; From the Division of Neuro-Oncology (T.A.N., N.K.M., I.C.A.-R., N.W., J.D.), Department of Neurology; Department of Pathology (M.M.-L.A.); Division of Hematology and Oncology (J.A., A.R.B., Y.J., Y.-B.A.C.), Department of Medicine; Division of Infectious Diseases (A.R.L.), Department of Medicine; and Department of Neurosurgery (B.V.N.), Massachusetts General Hospital, Boston., Letourneau AR; From the Division of Neuro-Oncology (T.A.N., N.K.M., I.C.A.-R., N.W., J.D.), Department of Neurology; Department of Pathology (M.M.-L.A.); Division of Hematology and Oncology (J.A., A.R.B., Y.J., Y.-B.A.C.), Department of Medicine; Division of Infectious Diseases (A.R.L.), Department of Medicine; and Department of Neurosurgery (B.V.N.), Massachusetts General Hospital, Boston., Nahed BV; From the Division of Neuro-Oncology (T.A.N., N.K.M., I.C.A.-R., N.W., J.D.), Department of Neurology; Department of Pathology (M.M.-L.A.); Division of Hematology and Oncology (J.A., A.R.B., Y.J., Y.-B.A.C.), Department of Medicine; Division of Infectious Diseases (A.R.L.), Department of Medicine; and Department of Neurosurgery (B.V.N.), Massachusetts General Hospital, Boston., Arrillaga-Romany IC; From the Division of Neuro-Oncology (T.A.N., N.K.M., I.C.A.-R., N.W., J.D.), Department of Neurology; Department of Pathology (M.M.-L.A.); Division of Hematology and Oncology (J.A., A.R.B., Y.J., Y.-B.A.C.), Department of Medicine; Division of Infectious Diseases (A.R.L.), Department of Medicine; and Department of Neurosurgery (B.V.N.), Massachusetts General Hospital, Boston., Wang N; From the Division of Neuro-Oncology (T.A.N., N.K.M., I.C.A.-R., N.W., J.D.), Department of Neurology; Department of Pathology (M.M.-L.A.); Division of Hematology and Oncology (J.A., A.R.B., Y.J., Y.-B.A.C.), Department of Medicine; Division of Infectious Diseases (A.R.L.), Department of Medicine; and Department of Neurosurgery (B.V.N.), Massachusetts General Hospital, Boston., Dietrich J; From the Division of Neuro-Oncology (T.A.N., N.K.M., I.C.A.-R., N.W., J.D.), Department of Neurology; Department of Pathology (M.M.-L.A.); Division of Hematology and Oncology (J.A., A.R.B., Y.J., Y.-B.A.C.), Department of Medicine; Division of Infectious Diseases (A.R.L.), Department of Medicine; and Department of Neurosurgery (B.V.N.), Massachusetts General Hospital, Boston. |
| Source: | Neurology [Neurology] 2024 Nov 12; Vol. 103 (9), pp. e209929. Date of Electronic Publication: 2024 Oct 04. |
| Publication Type: | Journal Article; Case Reports |
| Journal Info: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0401060 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1526-632X (Electronic) Linking ISSN: 00283878 NLM ISO Abbreviation: Neurology Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
